#USA #Alexandria #ZERO Prostate Cancer #Prostate Cancer Research #Medical Funding

ZERO Prostate Cancer Decries Major Funding Cuts

In a significant setback for prostate cancer research, ZERO Prostate Cancer's CEO, Courtney Bugler, has voiced profound disappointment following the House of Representatives' decision to approve a 57% funding cut to Congressionally Directed Medical Research Programs (CDMRP). This includes the Prostate Cancer Research Program (PCRP), which has been instrumental in developing FDA-approved treatments and saving lives across the nation.

The Impact of Funding Cuts

The eradication of funding for these critical programs poses a serious threat to ongoing medical advancements that have granted hope to countless individuals. Prostate cancer ranks as the second leading cause of cancer mortality among men, with alarming statistics indicating that veterans and active duty military personnel are diagnosed at rates twice that of the general population. Furthermore, the situation is stark for African American men, who show a 70% higher likelihood of developing prostate cancer and twice the mortality rate compared to their counterparts.

In 2025 alone, predictions suggest that 313,780 men will be diagnosed with prostate cancer, with over 35,000 expected to succumb to the disease. Currently, over 3 million men in America are living with prostate cancer. Given these statistics, it is imperative that PCRP funding remains intact to ensure vital research continues, especially at a time when the incidence of metastatic prostate cancer is rising due to insufficiencies in screening practices for those at heightened risk.

The Call to Action

In response to these budget cuts, ZERO Prostate Cancer is urging the Department of Defense to safeguard and prioritize funding for the PCRP. Bugler's statement underscores that “lives depend on it,” reflecting the urgency of the matter. ZERO is committed to advocating for enhanced awareness surrounding the importance of prostate cancer screening and the access to effective treatments, emphasizing that every patient should receive the support and care they need.

Since its inception nearly 30 years ago, ZERO Prostate Cancer has aimed to improve lives impacted by prostate cancer through advocacy, education, and comprehensive support. The organization, formerly known as the National Prostate Cancer Coalition, has become a leading voice in the fight against this disease. With a focus on closing gaps in diagnosis, treatment, and care, ZERO Prostate Cancer strives to break barriers to survival while addressing the needs of the most vulnerable populations affected by prostate cancer.

Looking Towards the Future

As the foremost provider of prostate cancer resources and services in the United States, ZERO Prostate Cancer has touched millions of lives, supporting patients and their families in their journey through diagnosis and treatment. The organization remains steadfast in its mission to ensure that all men have access to early detection, unwavering support, and necessary healthcare resources. With this fresh round of funding cuts, the need for advocacy and community mobilization has never been more urgent.

In light of these developments, ZERO will continue to campaign for increased awareness and essential funding to secure a future where prostate cancer can be effectively managed, diagnosed early, and treated promptly so that no patient feels alone in their fight against the disease.

For more information about ZERO Prostate Cancer and how to support their mission, visit ZEROcancer.org.